Under the agreement, Elekta will share identified sales opportunities for the Xoft Axxent Electronic Brachytherapy in the radiation oncology market. This non-exclusive agreement allows Elekta to expand its
Teva is currently involved in patent litigation with Wyeth concerning this product in the US District Court of New Jersey. In September 2007, the district court denied a
Applying its expertise in medicinal and synthetic chemistry, ChemDiv will support Achaogen in identifying and developing novel antibacterial compounds. Heinz Moser, senior vice president for chemistry at Achaogen,
This study builds on prior pharmacodynamic and safety data in a three-day study of TPI ASM8 in an allergen challenge model and will be conducted in collaboration with
Aggrastat is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and who are undergoing percutaneous transluminal coronary angioplasty. Outside of
The Phase I proof-of-concept trial is being conducted at a single center with approximately 30 healthy male volunteers and is designed to determine the safety, tolerability and pharmacokinetics
The primary objectives of the study are to determine the dose-limiting toxicity and maximum tolerated dose of AFP-464 in patients with advanced solid tumors. The trial is expected
The Fast Track drug development program is designed to promote the development of drugs to treat life-threatening or very serious conditions and requires that the drug demonstrate the
The Skylight Access Interactive Patient System uses a robust, dedicated fiber network infrastructure combined with a proprietary technology platform to offer exceptional bandwidth and speed, allowing extensive integrated
Aporo claims to provide significant clinical value by delivering novel transcatheter devices that close defects and then biodegrade over time, leaving behind no permanent implant. Initially, Aporo will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.